Aberdeen Group plc Cuts Position in Novavax, Inc. $NVAX

Aberdeen Group plc trimmed its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 41.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 37,188 shares of the biopharmaceutical company’s stock after selling 26,612 shares during the period. Aberdeen Group plc’s holdings in Novavax were worth $234,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of NVAX. Signaturefd LLC boosted its holdings in Novavax by 47.2% in the 2nd quarter. Signaturefd LLC now owns 9,739 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 3,122 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Novavax during the first quarter worth $71,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Novavax during the second quarter worth $73,000. GAMMA Investing LLC boosted its stake in shares of Novavax by 2,272.5% in the first quarter. GAMMA Investing LLC now owns 11,839 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 11,340 shares during the period. Finally, Kapitalo Investimentos Ltda acquired a new stake in Novavax during the 2nd quarter valued at $79,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Novavax Price Performance

Shares of NASDAQ NVAX opened at $8.10 on Friday. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of 3.55, a price-to-earnings-growth ratio of 0.11 and a beta of 2.74. Novavax, Inc. has a twelve month low of $5.01 and a twelve month high of $11.55. The business has a 50 day simple moving average of $8.43 and a 200-day simple moving average of $7.36.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.69. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. The firm had revenue of $239.24 million during the quarter, compared to the consensus estimate of $149.19 million. During the same quarter in the previous year, the company posted $0.99 earnings per share. The firm’s revenue was down 42.4% on a year-over-year basis. As a group, equities research analysts expect that Novavax, Inc. will post -1.46 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on NVAX shares. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novavax in a report on Wednesday, October 8th. HC Wainwright started coverage on Novavax in a research report on Thursday, August 28th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Bank of America reissued an “underperform” rating and issued a $7.00 price target (down previously from $9.00) on shares of Novavax in a report on Wednesday, August 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $9.80.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.